摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-丁氧基乙氧基)乙胺 | 6338-53-0

中文名称
2-(2-丁氧基乙氧基)乙胺
中文别名
——
英文名称
3,6-dioxadecylamine
英文别名
2-(2-butoxyethoxy)ethanamine;2-(2-butoxy-ethoxy)-ethylamine;2-(2-Butyloxy-aethoxy)-aethylamin;(2-Butyloxy-aethyl)-(2-amino-aethyl)-aether;2'-Amino-2-butyloxy-diaethylaether;2-(2-Butoxy-aethoxy)-aethylamin
2-(2-丁氧基乙氧基)乙胺化学式
CAS
6338-53-0
化学式
C8H19NO2
mdl
MFCD11196423
分子量
161.244
InChiKey
LVFVRCPHJZOLAT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    226.8±15.0 °C(Predicted)
  • 密度:
    0.911±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    11
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    44.5
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:4069fbf1da5743c001d0e1240eae5659
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
    申请人:Arvinas, Inc.
    公开号:US20190151295A1
    公开(公告)日:2019-05-23
    The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    本公开涉及双功能化合物,其作为白细胞介素-1受体相关激酶4(IRAK-4;目标蛋白)的调节剂具有实用性。具体而言,本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物,另一端结合目标蛋白的部分,使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解(和抑制)。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
  • [EN] BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY<br/>[FR] SOLVANTS BIODÉGRADABLES POUR L'INDUSTRIE CHIMIQUE
    申请人:UNIV DUBLIN CITY
    公开号:WO2009024607A1
    公开(公告)日:2009-02-26
    This invention relates to ionic liquid (ILs) solvents for chemical synthesis based on an alkyl - imidazolium cation core containing ionic liquids which have enhanced biodegradability and reduced toxicity relative to existing imidazolium bases ILs such as 1-butyl-3-methylimidazolium (bmmim) salts. Many of the described ILs produce a score of over 60% biodegradability over 28 days in a biodegradability test such as the Sturm Test, the Closed Bottle Test (OECD 301D) or the CO2 Headspace Test (ISO 14593). The ILs of the invention comprise an alkyl substituted imidazolium cationic core having a -C=OX- side chain in the 3-position of the imidazole ring, wherein X = O, NH, N or S and an associated counteranion characterized in that the -C=OX side chain comprises at least one ether linkage. The biodegradable and non-toxic IL may be used as green solvents for the chemical, pharmaceutical, biofuel and biomass industries. The ILs of the invention are particularly useful in hydrogenation, pericyclic and metathesis reactions.
    这项发明涉及一种基于含有烷基-咪唑啉阳离子核心的离子液体溶剂,用于化学合成,这些离子液体相对于现有如1-丁基-3-甲基咪唑啉(bmmim)盐类的咪唑啉基离子液体,具有增强的生物降解性和降低的毒性。所描述的许多离子液体在生物降解性测试中,例如Sturm测试、封闭瓶测试(OECD 301D)或CO2顶空测试(ISO 14593)中,28天内生物降解率超过60%。本发明的离子液体包括一个在咪唑啉环的3位上带有-C=OX-侧链的烷基取代咪唑啉阳离子核心,其中X=O,NH,N或S,以及一个相关的反离子,其特征在于-C=OX侧链至少包含一个醚键。这些生物降解且无毒的离子液体可作为化学、制药、生物燃料和生物质工业的绿色溶剂。特别是,本发明的离子液体在氢化、周环和复分解反应中非常有用。
  • ARYL SULFAMATE DERIVATIVES
    申请人:Kyowa Hakko Kogyo Co., Ltd
    公开号:EP1431280A1
    公开(公告)日:2004-06-23
    The present invention provides an aryl sulfamate derivative represented by Formula (I) (wherein Rr and Rs, which may be the same or different, each represent a hydrogen atom or lower alkyl, R1, R2, R3 and R4, which may be the same or different, each represent a hydrogen atom, lower alkyl, a halogen atom, nitro, cyano, azido, or the like, R5 represents a hydrogen atom, substituted or unsubstituted alkyl, substituted or unsubstituted lower cycloalkyl, or the like, R6 represents a hydrogen atom, substituted or unsubstituted alkyl, a halogen atom, or the like, or R5 and R6 are joined to form a bond, and R7 represents X1NR23R24 or COR26), or a pharmaceutically acceptable salt thereof.
    本发明提供了一种由式(I)表示的芳基磺酰胺衍生物(其中Rr和Rs可能相同也可能不同,分别表示氢原子或较低的烷基,R1、R2、R3和R4可能相同也可能不同,分别表示氢原子、较低的烷基、卤素原子、硝基、氰基、叠氮基等,R5表示氢原子、取代或未取代的烷基、取代或未取代的较低环烷基等,R6表示氢原子、取代或未取代的烷基、卤素原子等,或R5和R6连接形成键,R7表示X1NR23R24或COR26),或其药学上可接受的盐。
  • Intramolecular proton transfer impact on antibacterial properties of ansamycin antibiotic rifampicin and its new amino analogues
    作者:Krystian Pyta、Piotr Przybylski、Barbara Wicher、Maria Gdaniec、Joanna Stefańska
    DOI:10.1039/c2ob00008c
    日期:——
    Intramolecular proton transfer in rifampicin (1) and its analogues 2–9 with the formation of zwitterions has been indicated by multinuclear NMR and crystallographic studies. Biological tests of 1–9 in combination with the analysis of ligand–protein interactions have revealed the relationship between the protonation site and extremely high antibacterial activity.
    多核核磁共振和晶体学研究表明,利福平(1)及其类似物 2-9 中存在分子内质子转移,并形成了齐聚物。对 1-9 的生物测试以及配体与蛋白质相互作用的分析表明了质子化位点与极高抗菌活性之间的关系。
  • Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges
    作者:Natalia Skrzypczak、Krystian Pyta、Piotr Ruszkowski、Maria Gdaniec、Franz Bartl、Piotr Przybylski
    DOI:10.1016/j.ejmech.2020.112624
    日期:2020.9
    nucleophilic attack of amines at C(17) or C(17)/C(20) positions of geldanamycin’s (GDM) benzoquinone, via initial 1,4-Michael conjugate addition mechanism, yield new analogs with closed or open ansa-bridges (1-31), respectively. X-ray structures of analogs 22 and 24 reveals an unexpected arrangement of the ansa-bridge in solid (conformer B), that is located between those of conformers A, prevailing in solution
    胺的在C(17)或C(17)/ C的亲核攻击(20)格尔德霉素的(位置GDM)苯醌,经由初始1,4-迈克尔共轭加成机制,收率新类似物具有封闭或者打开的柄-bridges(1 - 31),分别。类似物的X射线结构22和24揭示了意想不到的排列柄-bridge在固体(构象异构体B)中,位于这些构象异构体A,在通行溶液(之间的反式β-内酰胺),和C,在关键结合Hsp90(顺式-内酰胺)。新型构象异构体B的结构可以更好地理解GDM类似物与目标Hsp90之间的分子识别机制。组合分析:抗癌测试结果(SKBR-3,SKOV-3,PC-3,U-87,A-549)和在正常细胞(HDF)中进行的测试,在Hsp90和c处的K D值和对接模式logP参数表明,具有H键受体作为羰基的C(17)刚性臂(哌啶基,环己基)和亲脂性clogP〜3有助于类似物的高效能,甚至在50到IC 50〜0.08μM与GDM相比,提高了选择性(SI
查看更多